Patents Assigned to AUTOLUS LIMITED
-
Patent number: 11965173Abstract: There is provided a plasmid system for transfection into a cell to create a producer cell, the system comprising: a. a helper plasmid comprising a first nucleotide sequence encoding Murine leukemia virus (MLV)-derived Gag and Pol poly-proteins; b. an envelope plasmid comprising a second nucleotide sequence encoding an Env protein; c. a genome plasmid comprising a third nucleotide sequence encoding a retroviral genome, wherein the first nucleotide sequence is codon-shuffled to remove any significant regions of homology with the third nucleotide sequence; and wherein the second nucleotide sequence is codon-optimised for expression in the producer cell.Type: GrantFiled: December 14, 2018Date of Patent: April 23, 2024Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Paulo Fernandes, Hanna Kymalainen, Ekaterini Kotsopoulou
-
Patent number: 11963981Abstract: The present invention provides a chimeric antigen receptor (CAR) which binds a target antigen having a bulky extracellular domain, wherein the CAR comprises a Fab antigen binding domain. The present invention also provides nucleic acid sequences and constructs encoding such a CAR, cells expressing such a CAR and their therapeutic uses.Type: GrantFiled: May 15, 2019Date of Patent: April 23, 2024Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Evangelia Kokalaki, Shaun Cordoba, Shimobi Onuoha, Simon Thomas, Biao Ma, Mathieu Ferrari
-
Patent number: 11959084Abstract: The present invention provides a nucleic acid construct comprising: a first nucleotide sequence of interest (NOI1); a frame-slip motif or a translational readthrough motif (FSM/TRM); and a second nucleotide sequence of interest (NOI2). The invention also provides vectors and cells expressing such a construct. The invention also provides a method for modulating the relative expression of two transgenes in a nucleic acid construct which comprises the step of including a frame-slip motif or a translational readthrough motif between the two transgenes in order to reduce the expression of the downstream transgene.Type: GrantFiled: July 31, 2019Date of Patent: April 16, 2024Assignee: AUTOLUS LIMITEDInventors: Shaun Cordoba, James Sillibourne, Martin Pulé
-
Patent number: 11945867Abstract: The present invention provides antibodies and polyclonal antibody preparations which bind the intracellular portion of either T-cell receptor constant region 2 (TRBC2) or T-cell receptor constant region 1 (TRBC1). The antibodies can be used to determine whether a T-cell malignancy clonally expresses TRBC1 or TRBC2.Type: GrantFiled: December 21, 2019Date of Patent: April 2, 2024Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Shimobi Onuoha, Ana Margarida Neves, Mathieu Ferrari, Paul Maciocia
-
Patent number: 11903967Abstract: The present invention provides a method of preparing a population of genetically modified cells which comprise a chimeric antigen receptor (CAR) or a transgenic T-cell receptor (TCR) comprising: providing a starting population of cells; depleting said starting population of cells which express a target antigen; and introducing into a cell in the depleted starting population a nucleic acid sequence which encodes a CAR or transgenic TCR against the target antigen. The present invention also provides genetically modified cells, pharmaceutical compositions and pharmaceutical compositions for use in the treatment and/or prevention of disease.Type: GrantFiled: November 12, 2018Date of Patent: February 20, 2024Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Carlotta Petticone, James Faulkner, Ekaterini Kotsopoulou, Emma Chan, Richard Beswick
-
Patent number: 11885807Abstract: The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TOR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.Type: GrantFiled: June 3, 2022Date of Patent: January 30, 2024Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Paul Maciocia
-
Patent number: 11885806Abstract: The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.Type: GrantFiled: June 3, 2022Date of Patent: January 30, 2024Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Paul Maciocia
-
Patent number: 11879016Abstract: Provision of a chimeric antigen receptor (CAR) comprising a disialoganglioside (GD2)-binding domain which comprises •a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: •b) a light chain variable region (VL) having CDRs with the following sequences: T cells expressing such a CAR are useful in the treatment of some cancers.Type: GrantFiled: March 9, 2021Date of Patent: January 23, 2024Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, John Anderson, Simon Thomas
-
Patent number: 11851672Abstract: The present invention provides a kit of vectors for transducing an immune cell with multiple transgenes comprising: (i) a first vector which comprises a first transgene and a nucleotide sequence encoding a transcription factor and; and (ii) a second vector which comprises a second transgene wherein expression of the second transgene within a host cell is dependent upon expression of the transcription factor.Type: GrantFiled: October 24, 2018Date of Patent: December 26, 2023Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, James Sillibourne, Shaun Cordoba
-
Patent number: 11814641Abstract: The present invention provides a retroviral or lentiviral vector having a viral envelope which comprises: (i) a mitogenic T-cell activating transmembrane protein which comprises a mitogenic domain and a transmembrane domain; and/or (ii) a cytokine-based T-cell activating transmembrane protein which comprises a cytokine domain and a transmembrane domain, wherein the mitogenic or cytokine-based T-cell activating transmembrane protein is not part of a viral envelope glycoprotein. When cells such as T-cells of Natural Killer cells are transduced by such a viral vector, they are simultaneously activated by the mitogenic T-cell activating transmembrane protein and/or the cytokine-based T-cell activating transmembrane protein.Type: GrantFiled: March 4, 2021Date of Patent: November 14, 2023Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Leila Mekkaoui
-
Patent number: 11701386Abstract: The present invention relates to a cell comprising a chimeric antigen receptor (CAR) and a constitutively active or inducible Signal Transducer and Activator of Transcription (STAT) molecule.Type: GrantFiled: September 12, 2018Date of Patent: July 18, 2023Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Shaun Cordoba, Simon Thomas, Shimobi Onuoha, Matteo Righi
-
Patent number: 11648274Abstract: The present invention provides a chimeric polypeptide comprising: an antigen-binding domain which constitutively binds to an ectodomain of a first chain of a cytokine receptor; a transmembrane domain; and an endodomain from a second chain of the cytokine receptor which chimeric polypeptide, when expressed in a cell, binds to the endogenous first chain of the cytokine receptor causing constitutive cytokine signalling.Type: GrantFiled: November 23, 2018Date of Patent: May 16, 2023Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Matteo Righi, Simon Thomas, Shimobi Onuoha, Shaun Cordoba
-
Patent number: 11643453Abstract: The present invention provides a cell which comprises; (i) a chimeric antigen receptor (CAR) or a transgenic T-cell receptor (TCR); and (ii) a polypeptide capable of co-localizing a beta-2 microglobulin component of a MHC class I molecule with an intracellular signalling domain within the cell.Type: GrantFiled: October 12, 2018Date of Patent: May 9, 2023Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, James Sillibourne, Lukas Stanczuk
-
Patent number: 11613559Abstract: The present invention provides a nucleic acid construct comprising the following structure: A-X-B in which A is nucleic acid sequence encoding a first polypeptide which comprises a first signal peptide; B is nucleic acid sequence encoding a second polypeptide which comprises a second signal peptide and X is a nucleic acid sequence which encodes a cleavage site, wherein the first signal peptide or the second signal peptide comprises one or more mutation(s) such that it has fewer hydrophobic amino acids.Type: GrantFiled: April 26, 2016Date of Patent: March 28, 2023Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Shaun Cordoba
-
Patent number: 11591613Abstract: The present invention provides a retroviral or lentiviral vector having a viral envelope which comprises a mitogenic T-cell activating transmembrane protein which comprises: (i) a mitogenic domain which binds a mitogenic tetraspanin, and (ii) a transmembrane domain; wherein the mitogenic T-cell activating transmembrane protein is not part of a viral envelope glycoprotein. When cells such as T-cells or Natural Killer cells are transduced by such a viral vector, they are activated by the mitogenic T-cell activating transmembrane protein.Type: GrantFiled: August 16, 2017Date of Patent: February 28, 2023Assignee: AUTOLUS LIMITEDInventors: Vijay Peddareddigari, Richard Beswick, John Short, Martin Pulé, Ekaterini Kotsopoulou
-
Patent number: 11590170Abstract: The present invention provides a chimeric antigen receptor (CAR) which binds a target antigen having a bulky extracellular domain, wherein the CAR comprises a Fab antigen binding domain. The present invention also provides nucleic acid sequences and constructs encoding such a CAR, cells expressing such a CAR and their therapeutic uses.Type: GrantFiled: April 18, 2022Date of Patent: February 28, 2023Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Evangelia Kokalaki, Shaun Cordoba, Shimobi Onuoha, Simon Thomas, Biao Ma, Mathieu Ferrari
-
Patent number: 11578126Abstract: There is provided a chimeric antigen receptor (CAR) comprising a CD19-binding domain which comprises a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: CDR1—GY-AFSSS (SEQ ID No. 1); CDR2—YPGDED (SEQ ID No. 2) CDR3—SLLYGDYLDY (SEQ ID No. 3); and b) a light chain variable region (VL) having CDRs with the following sequences: CDR1—SASSSVSYMH (SEQ ID No. 4); CDR2—DTSKLAS (SEQ ID No. 5) CDR3—QQWNINPLT (SEQ ID No. 6). There is also provided a cell comprising such a CAR, and the use of such a cell in the treatment of cancer, in particular a B cell malignancy.Type: GrantFiled: September 17, 2019Date of Patent: February 14, 2023Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Leila Mekkaoui, Persis Amrolia, Sara Ghorashian, Anne Kramer, Gordon Cheung
-
Patent number: 11530420Abstract: The present invention provides a nucleic acid construct comprising the following structure: A-X-B in which A and B are nucleic acid sequences encoding a first and a second polypeptide of interest (POI); and X is a nucleic acid sequence which encodes a cleavage site, wherein either the first or second POI is a transmembrane protein which comprises an intracellular retention signal.Type: GrantFiled: April 26, 2016Date of Patent: December 20, 2022Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Shaun Cordoba
-
Patent number: 11479614Abstract: The present invention provides a chimeric cytokine receptor (CCR) comprising: (i) an exodomain which binds to a ligand selected from a tumour secreted factor, a chemokine and a cell-surface antigen; and (ii) a cytokine receptor endodomain.Type: GrantFiled: August 20, 2020Date of Patent: October 25, 2022Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Shaun Cordoba, Matteo Righi, James Sillibourne, Shimobi Onuoha, Simon Thomas
-
Patent number: 11479613Abstract: The present invention provides a chimeric cytokine receptor (CCR) comprising: (i) an exodomain which binds to a ligand selected from a tumour secreted factor, a chemokine and a cell-surface antigen; and (ii) a cytokine receptor endodomain.Type: GrantFiled: August 20, 2020Date of Patent: October 25, 2022Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Shaun Cordoba, Matteo Righi, James Sillibourne, Shimobi Onuoha, Simon Thomas